COMBINE 2 was the first assessment of the efficacy and safety of once-weekly IcoSema vs once-weekly semaglutide 1.0 mg in individuals with type 2 diabetes inadequately managed with GLP-1 RA therapy, with or without additional oral glucose-lowering medications. Here, GLP1R is linked to type 2 diabetes mellitus.